Although Bobola et al (1996) showed that MGMT is a determinant of resistance in medulloblastoma and glioma-derived cell lines, they found disparity in the contribution of MGMT to TMZ sensitivity. The gene discussed is MGMT; the disease is central nervous system cancer.